Sugi Predict

Sugi Predict / Targets / TNFSF11

TNFSF11

Tumor necrosis factor ligand superfamily member 11 · O14788 · TNFSF11 on Sugi Atlas →

2,548 patent compounds predicted against TNFSF11, 1,378 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1270919 SCHEMBL1270919 1.00 11/20
SCHEMBL947109 SCHEMBL947109 0.74 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4950341) 0.73 7/20
SCHEMBL947717 SCHEMBL947717 0.65 7/20
SCHEMBL948005 SCHEMBL948005 0.65 7/20
SCHEMBL9150550 SCHEMBL9150550 0.56 7/20
SCHEMBL9149259 SCHEMBL9149259 0.50 7/20
SCHEMBL947418 SCHEMBL947418 0.68 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4944672) 0.59 6/20
SCHEMBL2845286 SCHEMBL2845286 0.53 6/20
SCHEMBL946363 SCHEMBL946363 0.47 5/20
SCHEMBL946508 SCHEMBL946508 0.67 4/20
SCHEMBL6278833 SCHEMBL6278833 0.63 4/20
SCHEMBL949155 SCHEMBL949155 0.59 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL946790) 0.58 4/20
SCHEMBL946303 SCHEMBL946303 0.58 4/20
SCHEMBL8999103 SCHEMBL8999103 0.57 4/20
SCHEMBL7799771 SCHEMBL7799771 0.55 4/20
SCHEMBL947245 SCHEMBL947245 0.51 4/20
SCHEMBL8227540 SCHEMBL8227540 0.51 4/20

Clinical trials — most relevant to TNFSF11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes PHASE4COMPLETED
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) PHASE4COMPLETED
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone PHASE3UNKNOWN
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease PHASE3RECRUITING
TNFSF11 Inhibition and Fertility: a Prospective Study PHASE2COMPLETED
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
NAPO - Novel Approach for Oligospermia PHASE1/PHASE2COMPLETED
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) PHASE2COMPLETED
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
Etanercept in Hidradenitis Suppurativa PHASE2COMPLETED
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients PHASE2COMPLETED
The Efficacy of Denosumab in Active Crohn's Disease PHASE1/PHASE2COMPLETED
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma PHASE1/PHASE2UNKNOWN
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) PHASE1COMPLETED
Presurgical Trial of Denosumab in Breast Cancer EARLY_PHASE1COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Effect of Smoking on Periodontal Therapy in Periodontitis nanCOMPLETED
Er,Cr:YSGG Laser Application in Peri-implantitis nanCOMPLETED
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions nanCOMPLETED
Interleukin-34 Level in Periodontal Disease nanUNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism nanCOMPLETED
TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) nanNOT_YET_RECRUITING
Effect of Double Antibiotic Paste Versus Calcium Hydroxide on RANKL/OPG Levels nanUNKNOWN
Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment nanUNKNOWN
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab nanNOT_YET_RECRUITING
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNFSF11 binder may also engage these)

ProteinNameSimilarity
Q9ESE2 — 0.998 Q9ESE2 →
O35235 — 0.997 O35235 →
Q9Z2V2 — 0.995 Q9Z2V2 →
P27548 — 0.992 P27548 →
Q8JFG3 — 0.992 Q8JFG3 →
P63304 — 0.991 P63304 →
CD40LG CD40 ligand 0.990 landscape →
Q98TB4 — 0.990 Q98TB4 →
P34822 — 0.989 P34822 →
B6ZK77 — 0.989 B6ZK77 →
O35312 — 0.989 O35312 →
P60029 — 0.989 P60029 →
Q91ZV7 — 0.989 Q91ZV7 →
P63305 — 0.988 P63305 →
P84903 — 0.988 P84903 →
Q4AEG6 — 0.988 Q4AEG6 →
Q8UWD9 — 0.988 Q8UWD9 →
P51749 — 0.988 P51749 →
Q9DC11 — 0.988 Q9DC11 →
P79374 — 0.988 P79374 →
O95393 — 0.988 O95393 →
P54631 — 0.988 P54631 →
Q9UK05 — 0.988 Q9UK05 →
Q7YQL9 — 0.988 Q7YQL9 →
P35546 — 0.988 P35546 →
STIM1 Stromal interaction molecule 1 0.988 landscape →
Q9XU98 — 0.988 Q9XU98 →
P59823 — 0.988 P59823 →
Q9R097 — 0.988 Q9R097 →
Q00495 — 0.988 Q00495 →